Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial

Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial

Objective To characterise the safety and efficacy of anifrolumab in active lupus nephritis (LN) through year 2 of the phase II randomised, double-blind Treatment of Uncontrolled Lupus via the Interferon Pathway (TULIP)-LN trial (NCT02547922) of 2 anifrolumab dosing regimens versus placebo.Methods Pa...

Full description

Bibliographic Details
Main Authors: Richard Furie, Raj Tummala, Brad Rovin, Frederic Houssiau, David Jayne, Eduardo Mysler, Teodora Trasieva, Catharina Lindholm, Jacob Knagenhjelm, Erik Schwetje, Weifeng Tang
Format: Article
Language:English
Published: BMJ Publishing Group 2023-10-01
Series:Lupus Science and Medicine
Online Access:https://lupus.bmj.com/content/10/2/e000910.full

Internet

https://lupus.bmj.com/content/10/2/e000910.full

Similar Items